Evidence map›Paper›PMID 42216109›Full record

ArticleCell & bioscience2026

Decoding the role of H19 in cholestatic liver injury using snRNA-seq, spatial transcriptomics, and machine learning-based disease prediction.

Grayson W Way, Xixian Jiang, Hongkun Lu, Nan Wu, Derrick Zhao, Yun-Ling Tai, Sareh Bayatpour, Xuan Wang, Huiping Zhou

Abstract read
In one paragraph

Article in Cell & bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Grayson W WayDepartment of Microbiology and Immunology, Richmond VA Medical Center, Virginia Commonwealth University, 1220 East Broad Street, MMRB-5044, Richmond, VA, 23298-0678, USA.
Xixian JiangDepartment of Microbiology and Immunology, Richmond VA Medical Center, Virginia Commonwealth University, 1220 East Broad Street, MMRB-5044, Richmond, VA, 23298-0678, USA.
Hongkun LuDepartment of Microbiology and Immunology, Richmond VA Medical Center, Virginia Commonwealth University, 1220 East Broad Street, MMRB-5044, Richmond, VA, 23298-0678, USA.
Nan WuDepartment of Microbiology and Immunology, Richmond VA Medical Center, Virginia Commonwealth University, 1220 East Broad Street, MMRB-5044, Richmond, VA, 23298-0678, USA.
Derrick ZhaoDepartment of Microbiology and Immunology, Richmond VA Medical Center, Virginia Commonwealth University, 1220 East Broad Street, MMRB-5044, Richmond, VA, 23298-0678, USA.
Yun-Ling TaiDepartment of Microbiology and Immunology, Richmond VA Medical Center, Virginia Commonwealth University, 1220 East Broad Street, MMRB-5044, Richmond, VA, 23298-0678, USA.
Sareh BayatpourDepartment of Microbiology and Immunology, Richmond VA Medical Center, Virginia Commonwealth University, 1220 East Broad Street, MMRB-5044, Richmond, VA, 23298-0678, USA.
Xuan WangDepartment of Microbiology and Immunology, Richmond VA Medical Center, Virginia Commonwealth University, 1220 East Broad Street, MMRB-5044, Richmond, VA, 23298-0678, USA.
Huiping ZhouDepartment of Microbiology and Immunology, Richmond VA Medical Center, Virginia Commonwealth University, 1220 East Broad Street, MMRB-5044, Richmond, VA, 23298-0678, USA. huiping.zhou@vcuhealth.org.

Funding

Mouse Model and Pathological Analysis CoreP01CA275740 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Devanand Sarkar · 2024 to 2026
$10.6M
Circular RNAs in Cholestatic Liver DiseasesR01DK139587 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI HUIPING ZHOU · 2024 to 2026
$2.2M
LncRNA H19 in Cholestatic Liver DiseasesR01DK115377 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI HYLEMON, PHILLIP B, ZHOU, HUIPING ROSE · 2018 to 2021
$2.1M
Sphingolipids in alcoholic liver diseaseR01AA030180 · NIAAA · VIRGINIA COMMONWEALTH UNIVERSITY · PI PHILLIP B HYLEMON, HUIPING ZHOU · 2023 to 2026
$2.1M
Cross-Species Multidisciplinary Training in Alcohol ResearchT32AA029975 · NIAAA · VIRGINIA COMMONWEALTH UNIVERSITY · PI MICHAEL F MILES, Brien P Riley · 2023 to 2026
$1.5M
LncRNA H19 in Cholestatic Liver DiseasesR56DK115377 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI HYLEMON, PHILLIP B, ZHOU, HUIPING ROSE · 2023 to 2023
$630k
BLRD VA I01 BX005730BLRD VA IK6 BX004477BLRD VA IS1 BX004777BLRD VA IS1 BX005517NCI NIH HHS P01 CA275740NIAAA NIH HHS R01 AA030180NIAAA NIH HHS T32 AA029975NIDDK NIH HHS R01 DK115377NIDDK NIH HHS R01 DK139587NIDDK NIH HHS R56 DK115377NIH HHS 5T32AA029975NIH HHS DK115377, 2R56DK115377-05A1, 5R01AA030180, R01DK139587, NIH-NCI P01CA275740U.S. Department of Veterans Affairs 5I01BX005730,1 IS1 BX004777-01 and 1IS1BX005517-01, IK6BX004477
6 · The paper itself

Abstract

backgroundDespite recent advances, Primary Sclerosing Cholangitis (PSC)-a chronic obstructive biliary disease-still lacks effective therapies to prevent disease progression or the need for liver transplantation. Moreover, up to 30% of transplant recipients experience recurrence. Long non-coding RNA H19 (H19) has been implicated in promoting PSC progression, yet the cellular and molecular mechanisms underlying its pathogenic role remain incompletely understood.

resultsLiver tissues from age- and sex-matched wild type (WT), H19 knockout (H19KO), Mdr2 knockout (Mdr2KO), and double-knockout (DKO; Mdr2KO/H19KO) mice were analyzed using single-nucleus RNA sequencing (snRNAseq) and GeoMx spatial transcriptomics to define the cell type and spatially specific effects of H19 deletion in cholestatic liver injury. Machine learning models were built to develop cell-type-specific gene prediction signatures and cross-validated using the human dataset GSE243981. A disease-associated cholangiocyte subcluster that increased in Mdr2KO but was markedly reduced in DKO mice was identified. SPP1 signaling was significantly dysregulated in cholestatic liver injury and mitigated following H19 deletion. Translationally conserved healthy (Clu, Spp1) and diseased (Csmd1, Slco3a1, Cftr) cholangiocyte markers were identified. When validated in a human patient dataset (GSE243981), our machine-learning prediction models achieved AUC values > 0.869. Finally, spatial analyses demonstrated that the mitigation of disease-associated gene expression following H19 deletion was specifically restricted to hepatocytes within the bile duct region.

conclusionsH19 deletion mitigates cholestatic injury by suppressing pathogenic cholangiocyte states, normalizing Spp1-mediated signaling, and shifting transcriptional programs specifically within the periductal niche. Furthermore, our machine-learning signatures demonstrate robust cross-species translation and may benefit future post-transplant analytics and disease recurrence predictions.

Indexed as

CholestasisH19Long non-coding RNAMachine learningPrimary sclerosing cholangitisSPP1

Identifiers

PMID42216109
PMCPMC13425977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.